Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic options for triple-negative breast cancers with defective homologous recombination.

Biochimica et biophysica acta - 1 Dec 2009

Jaspers Janneke E, Rottenberg Sven, Jonkers Jos

Abstract excerpt

Breast cancer is the most common malignancy among women in developed countries, affecting more than a million women per year worldwide. Over the last decades, our increasing understanding of breast cancer biology has led to the development of endocrine agents against hormone receptor-positive tumors and targeted therapeutics against HER2-expressing tumors. However, no targeted therapy is available for patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Drug Resistance, Neoplasm
Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Protein Kinase Inhibitors

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Source

Identifiers

PMID: 19616605
DOI: 10.1016/j.bbcan.2009.07.001

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic options for triple-negative breast cancers with defective homologous recombination.PMID 19616605Read ↗

Biology and Management of Patients With Triple-Negative Breast CancerSemantic proximity Read ↗

Triple-Negative Breast Cancer: Molecular Particularities Still a ChallengeSemantic proximity Read ↗

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.Semantic proximity Read ↗

Treatment options for patients with triple-negative breast cancer.Semantic proximity Read ↗

Triple-negative breast cancer: from none to multiple therapeutic targets in two decadesSemantic proximity Read ↗

[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].Semantic proximity Read ↗

Homologous recombination deficiency in triple negative breast cancerSemantic proximity Read ↗

Triple-negative breast cancer.Semantic proximity Read ↗

Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.Semantic proximity Read ↗

Triple-negative breast cancer.Semantic proximity Read ↗

BRCA Gene Structure and Function in Tumor SuppressionSemantic proximity Read ↗

NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.